Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436

Watchlist Manager
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Logo
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Watchlist
Price: 202.72 CNY -0.21% Market Closed
Market Cap: 122.3B CNY

Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Operating Activities
ÂĄ1.1B
CAGR 3-Years
22%
CAGR 5-Years
-7%
CAGR 10-Years
17%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Operating Activities
ÂĄ4.7B
CAGR 3-Years
22%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Operating Activities
ÂĄ7.4B
CAGR 3-Years
21%
CAGR 5-Years
14%
CAGR 10-Years
17%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Operating Activities
ÂĄ4.3B
CAGR 3-Years
-6%
CAGR 5-Years
15%
CAGR 10-Years
10%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Cash from Operating Activities
-ÂĄ705.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Operating Activities
-ÂĄ615.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Glance View

Market Cap
122.3B CNY
Industry
Pharmaceuticals

Zhangzhou Pientzehuang Pharmaceutical Co. Ltd., nestled in the heart of Fujian Province, China, is a firm steeped in history and tradition, yet thriving in today’s modern pharmaceutical landscape. The company is best known for its signature product, Pientzehuang Pills, a centuries-old traditional Chinese medicine believed to offer hepatoprotective and detoxifying properties. Rooted in ancient formulations, Pientzehuang Pills are celebrated for their efficacy in addressing liver ailments and enhancing overall vitality. This has secured their place as a staple in Chinese households, maintaining cultural resonance while appealing to a broader audience through the global rise in demand for alternative medicine. The firm operates with a delicate balance, integrating traditional Chinese medicine practices with increasingly sophisticated production technologies to ensure quality consistency and scalability. Zhangzhou Pientzehuang leverages its brand heritage and expertise in traditional herbal remedies to drive revenue. The company has adeptly positioned itself within both domestic and international markets, capitalizing on the growing interest in holistic health approaches. By focusing on research and development, the company continues to innovate, expanding its product line to include health supplements and preventive solutions that cater to modern health challenges. Its strategic distribution channels, including hospitals, pharmacies, and online platforms, enable broad market penetration, ensuring robust sales growth. This dual strategy of preserving the traditional while embracing the modern allows the company to keep its legacy relevant in a competitive pharmaceutical industry, thereby securing its stronghold in the market and ensuring sustained financial performance.

Intrinsic Value
178.67 CNY
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
1.1B CNY

Based on the financial report for Sep 30, 2024, Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Cash from Operating Activities amounts to 1.1B CNY.

What is Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
17%

Over the last year, the Cash from Operating Activities growth was -63%. The average annual Cash from Operating Activities growth rates for Zhangzhou Pientzehuang Pharmaceutical Co Ltd have been 22% over the past three years , -7% over the past five years , and 17% over the past ten years .

Back to Top